APA (7th ed.) Citation

R, M., F, d. l. C., M, V., C, G., J, Q., M, J., . . . JR, A. (2023). Tenofovir Disoproxil Fumarate/Emtricitabine and Baricitinib for Patients at High Risk of Severe Coronavirus Disease 2019: The PANCOVID Randomized Clinical Trial. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 76(3), e116. https://doi.org/10.1093/cid/ciac628

Chicago Style (17th ed.) Citation

R, Montejano, et al. "Tenofovir Disoproxil Fumarate/Emtricitabine and Baricitinib for Patients at High Risk of Severe Coronavirus Disease 2019: The PANCOVID Randomized Clinical Trial." Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America 76, no. 3 (2023): e116. https://doi.org/10.1093/cid/ciac628.

MLA (9th ed.) Citation

R, Montejano, et al. "Tenofovir Disoproxil Fumarate/Emtricitabine and Baricitinib for Patients at High Risk of Severe Coronavirus Disease 2019: The PANCOVID Randomized Clinical Trial." Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, vol. 76, no. 3, 2023, p. e116, https://doi.org/10.1093/cid/ciac628.